Inactive Instrument

Highlights Veru Inc Nasdaq

Equities

US3144621022

Highlights

Unlock all the news: Be the first to know and act before the market!

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	05-22	CI
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-08	CI
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	05-08	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	04-30	CI
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	04-01	CI
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	02-06	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	01-08	CI
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-08	CI
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	04/10/23	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	26/09/23	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	11/09/23	CI
Earnings Flash (VERU) VERU Posts Q3 Revenue $3.3M	10/08/23	MT
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	10/08/23	CI
Earnings Flash (VERU) VERU Reports Q2 Revenue $6.6M	11/05/23	MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	11/05/23	CI
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS	04/05/23	CI
Veru Sells Entadfi Business for $20 Million Plus Up to $80 Million From Sales Milestones; Shares Up Pre-Bell	20/04/23	MT
Veru Sets Accord With Afaxys to Offer FC2 Female Condom in US Public Health Centers	19/04/23	MT
Veru Says Preclinical Data Show Sabizabulin Inhibits Poxviruses; Shares Rise	11/04/23	MT
Veru Says Influenza Drug Candidate Showed 'Robust' Anti-Inflammatory Activity in Animal Study	04/04/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Veru Inc Nasdaq

Equities

US3144621022

Highlights

Filters